Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK; DLB/PDD Working Group. Lippa CF, et al. Among authors: fahn s. Neurology. 2007 Mar 13;68(11):812-9. doi: 10.1212/01.wnl.0000256715.13907.d3. Neurology. 2007. PMID: 17353469 Review.
Selegiline and mortality in Parkinson's disease.
Olanow CW, Fahn S, Langston JW, Godbold J. Olanow CW, et al. Among authors: fahn s. Ann Neurol. 1996 Dec;40(6):841-5. doi: 10.1002/ana.410400605. Ann Neurol. 1996. PMID: 9007088 Review. No abstract available.
The role of radiotracer imaging in Parkinson disease.
Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R. Ravina B, et al. Among authors: fahn s. Neurology. 2005 Jan 25;64(2):208-15. doi: 10.1212/01.WNL.0000149403.14458.7F. Neurology. 2005. PMID: 15668415 Review.
Freezing of gait in PD: prospective assessment in the DATATOP cohort.
Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C; Parkinson Study Group. Giladi N, et al. Among authors: fahn s. Neurology. 2001 Jun 26;56(12):1712-21. doi: 10.1212/wnl.56.12.1712. Neurology. 2001. PMID: 11425939 Clinical Trial.
Fatigue in levodopa-naive subjects with Parkinson disease.
Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators. Schifitto G, et al. Among authors: fahn s. Neurology. 2008 Aug 12;71(7):481-5. doi: 10.1212/01.wnl.0000324862.29733.69. Neurology. 2008. PMID: 18695158 Free PMC article. Clinical Trial.
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.
Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Pankratz N, et al. Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687. Ann Neurol. 2012. PMID: 22451204 Free PMC article.
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group. Shoulson I, et al. Among authors: fahn s. Ann Neurol. 2002 May;51(5):604-12. doi: 10.1002/ana.10191. Ann Neurol. 2002. PMID: 12112107 Clinical Trial.
612 results